In the CY 2025 PFS final rule (89 FR 98228 through 98275), we codified regulations implementing section 11101 of the IRA in newly added 42 CFR part 427, chapter IV, including new provisions at 427.200 and 427.201 to codify the policies regarding the computation of the inflation-adjusted beneficiary coinsurance, defined in 427.200, for Part B rebatable drugs as required by section 1847A(i)(5) of the Act
Supplied as a high-purity lyophilized peptide blend with full COA traceability
Cognitive Enhancement Research Dihexa Dihexa has been directly tested in cognitive paradigms (aged rat water maze, scopolamine reversal) and demonstrates synaptogenesis through HGF/c-Met signaling, providing a more direct cognitive enhancement rationale than PE-22-28 Neurogenesis and Mood Research PE-22-28 PE-22-28 induces hippocampal neurogenesis within 4 days and demonstrates antidepressant-like effects through TREK-1 blockade, making it more relevant for mood-cognition intersection research Oral Bioavailability Requirement Dihexa Dihexa has demonstrated approximately 38% oral bioavailability with BBB penetration, while PE-22-28 oral availability has not been characterized Lower Theoretical Risk Profile PE-22-28 PE-22-28 targets an ion channel without known oncological associations, whereas Dihexa activates the HGF/c-Met pathway which is a characterized oncogenic signaling axis Evidence Reliability PE-22-28 PE-22-28 has no retracted publications in its evidence base, while a key 2014 Dihexa paper was retracted for data fabrication concerns Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly
As a result, IgM OSE have been shown to reduce atherosclerosis in mice and to be inversely associated with coronary artery disease and coronary events in humans 127,128,129,130,131
Current Opinion in Clinical Nutrition and Metabolic Care, 14 (1), 28-34
ACE2 and ACE together take part in renin angiotensin system (RAS)
